Arbutus Biopharma Corporation (ABUS)
NASDAQ · Manufacturing · Pharmaceutical preparations
ABUS price, last 12 months
Key stats
- Previous close
- $4.11
- Open
- $4.12
- Day range
- $4.05 – $4.16
- 52-week range
- $3.50 – $5.45
- Volume
- 2.4M
- Avg volume (20 days)
- 2.5M
- Market cap
- $627.0M
Performance
Technicals and fundamentals
About Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $627.0M